How feasible is the global elimination of HCV infection?

The introduction of direct-acting antiviral agents in 2013 revolutionised the treatment of hepatitis C virus (HCV) infection.1 With duration of therapy as short as 8 weeks, few side-effects, the fact that more than 90% of patients can be cured, and more affordable drug prices following the introduction of generics, treatment has become a realistic option for many people living with HCV infection. In 2016, approximately 1·5 million people received HCV treatment.2 These treatment-related developments along with an improved understanding of the substantial global morbidity and mortality attributable to viral hepatitis led to increased advocacy for more action to address hepatitis.